KA Imaging Unveils New Brand Identify for its Patented Dual Energy Technology

SpectralDR™ is built into the Reveal™ 35C detector and family of products

Canadian manufacturer KA Imaging unveiled a new brand identity for its patented dual-energy technology. SpectralDR™ is currently built into the Reveal™ 35C detector. The new brand is in line with the company’s strategy to expand its presence in the X-ray market.

“The Reveal™ 35C detector is a breakthrough and the first in an exciting product roadmap,” said Fernanda Fraga, Marketing Manager of KA Imaging. At this time, Reveal™ 35C detector is available for sale in Canada, the United States, and other countries globally. Earlier this year, the company announced plans to develop an integrated mobile system powered by its SpectralDR™ technology.

KA Imaging’s SpectralDR™ technology enables dual-energy subtraction, providing bone and tissue differentiation with a single standard X-ray exposure. It acquires three images simultaneously (DR, bone and soft tissue dual-energy X-ray images). The technology mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray detectors.

“It’s a 3-in-1 solution, as in three images with one exposure to radiation and no extra work. Having a DR plus the supplemental spectral bone and tissue images allows for better diagnosis and faster reading,” said Dr. Phil Templeton, radiologist, and Chief Medical Officer of KA Imaging. The spectral images provide enhanced visualization of different conditions like lung nodules, pneumonia, tips of lines and tubes, pneumothorax and retained surgical bodies.

Adding a name to the patented technology simplifies the message to the industry. “SpectralDR™ addresses the drawbacks of previous dual-energy subtraction or bone suppression approaches,” said Dr. Karim S. Karim, CTO of KA Imaging.  Conventional dual energy is not mobile and uses two exposures, while bone suppression image quality is limited and cannot provide bone images. “SpectralDR™ really takes general X-ray to the next level because you can get true bone and soft tissue subtracted images every time plus a DR image in one exposure at the lowest dose. If it’s low dose, 3-in-1, and mobile and single exposure, you can bet it is powered by SpectralDR™, said Karim.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version